Sandostatin (USD 312 million, +11% cc) benefited from increasing use of Sandostatin LAR in treating the symptoms of neuroendocrine tumors (NET).
Sandostatine (USD 312 millions, +11% tcc) a bénéficié d’une utilisation accrue de Sandostatine LAR contre les tumeurs neuroendocrines (TNE).